Phase 1 trials today

The Molecular Basis of Cancer

Volumn , Issue , 2008, Pages 553-570

  LoRusso, Patricia M ^a   Nebiyou Bekele, B ^b   Boerner, Scott A ^c   Davis, Darren W ^d   Evelhoch, Jeffrey L ^e   Herbst, Roy S ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ApoCell Inc ^*  (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859849559     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603703-3.10047-0     Document Type: Chapter

References (136)

1. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005, 352:895.
2. Trump DL Hospice benefits and phase I cancer trials. Ann Int Med 2004, 140:70-71. author reply 71.
3. Travis K For phase I studies, ethical and practical concerns abound. J Natl Cancer Inst 2004, 96:1354.
4. Agrawal M, Emanuel EJ Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA 2003, 290:1075.
5. Roberts D, Lockley W Radiosynthesis-a vital role supporting drug development?. Drug Discovery World 2004, 5:59.
6. Rudin M, Weissleder R Molecular imaging in drug discovery and development. Nature Rev 2003, 2:123.
7. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005, 11:7967.
8. Guidance for Industry - In vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis and Recommendations for Dosing and Labelling November 1999, United States Food and Drug Administration.
9. Rahman A, White RM Cytotoxic anticancer agents and renal impairment study: the challenge remains. J Clin Oncol 2006, 24:533.
10. Takimoto CH, Mita AC Design, conduct, and interpretation of organ impairment studies in oncology patients. J Clin Oncol 2006, 24:3509-3510; author reply 10.
11. Ramanathan RK, Remick SC, Mulkerin D, et al. P-5331: A phase I pharmacokinetic (PK) study of STI571 in patients (pts) with advanced malignancies and varying degrees of liver dysfunction (LD). Proc Am Soc Clin Oncol 2003, 22:2003. abstr 502.
12. Remick SC, Ramanathan RK, Mulkerin D, et al. P-5340: A phase I pharmacokinetic study of STI-571 in patients (pts) with advanced malignancies and varying degrees of renal dysfunction. Proc Am Soc Clin Oncol 2003, 22:2003. abstr 503.
13. Doroshow JH, Synold TW, Gandara D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003, 30:14.
14. Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003, 21:2664.
15. Takimoto CH, Remick SC, Sharma S, et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. Semin Oncol 2003, 30:20.
16. The clinical evaluation of qt/qtc interval prolongation and proarrythmic potential for non-antiarrythmic drugs ICH Harmonized Tripartite Guideline, E14, 12 May 2005.
17. LoRusso PM, Heath E, Valdivieso M, et al. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006, 18S(3034).
18. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89:1138.
19. Collins JM, Zaharko DS, Dedrick RL, et al. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986, 70:73-80. 1986.
20. Omura GA Modified Fibonacci search. J Clin Oncol 2003, 21:3177.
21. Schneiderman MA Mouse to man: statistical problems in bringing a drug to clinical trial. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, vol. IV 1967, 855. University of California Press, Berkeley, CA.
22. Storer BE Design and analysis of phase I clinical trials. Biometrics 1989, 45:925-937.
23. Rubinstein L, Simon R Phase 1 clinical trial design. Handbook of Anticancer Drug Development 2003, 297. Lippincott Williams & Wilkins, Baltimore, Baltimore. D.R. Budman, A.H. Calvert, E.K. Rowinsky (Eds.).
24. Alousi AM, Parchment R, Boinpally R, et al. Phase I clinical trial of XK469 in patients with chemo-refractory solid tumors. J Clin Oncol 2004, 22:2020.
25. Gadgeel SM, Boinpally RR, Heilbrun LK, et al. A phase 1 clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design. Invest New Drugs 2003, 21:63.
26. Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase 1 clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005, 11:6233.
27. LoRusso PM, Foster BJ, Wozniak A, et al. Phase 1 pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res 2000, 6:3088.
28. LoRusso PM, Prakash S, Wozniak A, et al. Phase 1 clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU). Invest New Drugs 2002, 20:63.
29. Eisenhauer EA Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann Oncol 1998, 9:1047.
30. Hunsberger S, Rubinstein LV, Dancey J Dose escalation trial designs based on a molecularly targeted endpoint. Statistics Med 2005, 24:2171.
31. Korn EL. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. J Natl Cancer Inst 2004, 96:977.
32. Zhang W, Sargent DJ, Mandrekar S. An adaptive dose-finding design incorporating both toxicity and efficacy. Statistics Med 2006, 25:2365.
33. Collins JM, Grieshaber CK, Chabner BA Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 1990, 82:1321.
34. Collins JM Innovations in phase 1 trial design: where do we go next?. Clin Cancer Res 2000, 6:3801.
35. Fuse E, Kobayashi T, Inaba M, et al. Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics. Cancer Treat Rev 1995, 21:133.
36. Dees EC, Whitfield LR, Grove WR, et al. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. Clin Cancer Res 2000, 6:3885.
37. O'Quigley J, Pepe M, Fisher L Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990, 46:33.
38. Garrett-Mayer E The continual reassessment method for dose-finding studies: a tutorial. Clinical Trials (London, England) 2006, 3:57.
39. Ivanova A, Montazer-Haghighi A, Mohanty SG, et al. Improved up-and-down designs for phase I trials. Statistics Med 2003, 22:69.
40. Rosenberger WF, Haines LM Competing designs for phase I clinical trials: a review. Statistics Med 2002, 21:2757.
41. Cheung YK, Chappell R Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000, 56:1177.
42. Braun TM, Yuan Z, Thall PF Determining a maximum-tolerated schedule of a cytotoxic agent. Biometrics 2005, 61:335.
43. O'Quigley J, Hughes MD, Fenton T Dose-finding designs for HIV studies. Biometrics 2001, 57:1018.
44. Ivanova A A new dose-finding design for bivariate outcomes. Biometrics 2003, 59:1001.
45. Braun TM The bivariate continual reassessment method extending the CRM to phase I trials of two competing outcomes. Control Clin Trials 2002, 23:240.
46. Thall PF, Cook JD Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004, 60:684.
47. Bekele BN, Shen Y A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 2005, 61:343.
48. Bekele BN, Thall PF Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J American Statistical Assoc 2004, 99:26.
49. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659.
50. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60.
51. Dancey JE, Chen HX Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Rev 2006, 5:649.
52. Davis DW, McConkey DJ, Abbruzzese JL, et al. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003, 89:8.
53. Dowlati A, Haaga J, Remick SC, et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001, 7:2971.
54. Rimm DL What brown cannot do for you. Nat Biotechnol 2006, 24:914.
55. Davis DW, Takamori R, Raut CP, et al. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 2005, 11:678.
56. Davis DW, Shen Y, Mullani NA, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004, 10:33.
57. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002, 20:3804.
58. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999, 59:5412.
59. Berger AJ, Davis DW, Tellez C, et al. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005, 65:11185-11192.
60. Cregger M, Berger AJ, Rimm DL Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006, 130:1026.
61. Xiong HQ, Herbst R, Faria SC, et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 2004, 22:459.
62. Davis DW, Buchholz TA, Hess KR, et al. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 2003, 9:955.
63. Davis DW, McConkey DJ, Heymach JV, et al. Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248. Proc Am Soc Clin Oncol 2005, 23:2005.
64. Mendelsohn J, Baselga J Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33:369.
65. Hubbard SR Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 1999, 71:343.
66. Bernatchez PN, Soker S, Sirois MG Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 1999, 274:31047-31054.
67. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237.
68. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149.
69. Daneshmand M, Parolin DA, Hirte HW, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003, 9:2457-2464.
70. Busse D, Doughty RS, Ramsey TT, et al. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 2000, 275:6987.
71. Gasparini G, Sarmiento R, Amici S, et al. Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Ann Oncol 2005, 16:1867.
72. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002, 20:110.
73. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature .
74. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277.
75. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002, 20:3792.
76. Anderson NG, Maller JL, Tonks NK, et al. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990, 343:651.
77. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999, 5:810.
78. LoRusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005, 23:5281.
79. An WG, Hwang SG, Trepel JB, et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14:1276.
80. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin- dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997, 11:342.
81. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609.
82. Hamilton AL, Eder JP, Pavlick AC, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic endpoints using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 2005, 23:6107.
83. Boguski MS, McCormick F Proteins regulating Ras and its relatives. Nature 1993, 366:643.
84. Bos JL Ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689. 1989.
85. Hunt JT, Ding CZ, Batorsky R, et al. Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem 2000, 43:3587.
86. Tabernero J, Rojo F, Marimon I, et al. Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2005, 23:2521.
87. Du W, Liu A, Prendergast GC Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 1999, 59:4208.
88. O'Hara SM, Moreno JG, Zweitzig DR, et al. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem 2004, 50:826.
89. Gordon Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients (PTS) with metastatic cancer. Proc Am Soc Clin Oncol 1998, 17.
90. Clin Pharmacol Ther 2001, 69:89. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.
91. Frank R, Hargreaves R Clinical biomarkers in drug discovery and development. Nature Rev 2003, 2:566.
92. Collins JM Functional imaging in phase I studies: decorations or decision making?. J Clin Oncol 2003, 21:2807.
93. Bergstrom M, Grahnen A, Langstrom B Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003, 59:357.
94. Saleem A, Brown GD, Brady F, et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003, 63:2409.
95. Philpott GW, Schwarz SW, Anderson CJ, et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995, 36:1818.
96. Kissel J, Brix G, Bellemann ME, et al. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997, 57:3415.
97. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002, 94:1484.
98. Van Den Bossche B, de Wiele C Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 2004, 22:3593.
99. Workman P, Aboagye EO, Chung YL, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 2006, 98:580.
100. Jain RK Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990, 50:814s-19s.
101. Schwartz JL, Tamura Y, Jordan R, et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003, 44:2027.
102. Zhou D, Chu W, Rothfuss J, et al. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 2006, 16:5041.
103. Lahorte CM, Vanderheyden JL, Steinmetz N, et al. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004, 31:887.
104. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004, 6:831.
105. Zhao M, Pipe JG, Bonnett J, et al. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 1996, 73:61.
106. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006, 12:3942.
107. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003, 63:5838.
108. McQuade P, Knight LC Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). Q J Nucl Med 2003, 47:209.
109. Haubner RH, Wester HJ, Weber WA, et al. Radiotracer-based strategies to image angiogenesis. Q J Nucl Med 2003, 47:189.
110. Galbraith SM MR in oncology drug development. NMR Biomed 2006, 19:681.
111. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005, 92:1599.
112. Evelhoch J, Garwood M, Vigneron D, et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res 2005, 65:7041.
113. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004, 10:3650.
114. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003, 21:2831-28342.
115. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002, 20:3826.
116. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005, 23:5464.
117. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21:3955.
118. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005, 23:5474.
119. Collins JM Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?. J Clin Oncol 2005, 23:5417.
120. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005, 11:2785.
121. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001, 42:1551.
122. de Geus-Oei L-F, Krieken JHJMv, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2006, In press.
123. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472.
124. Barnes K, McIntosh E, Whetton AD, et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 2005, 24:3257.
125. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205.
126. Husband JE, Schwartz LH, Spencer J, et al. Evaluation of the response to treatment of solid tumours-a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004, 90:2256.
127. Twombly R Criticism of tumor response criteria raises trial design questions. J Natl Cancer Inst 2006, 98:232.
128. Schwartz LH, Mazumdar M, Wang L, et al. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer 2003, 98:1611.
129. Moertel CG, Hanley JA The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976, 38:388-394.
130. Michaelis LC, Ratain MJ Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006, 6:409.
131. Lavin PT An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 1981, 4:451-457.
132. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004, 22:175.
133. Dowlati A, Robertson K, Radivoyevitch T, et al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 2005, 11:7938.
134. Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 2001, 7:3366.
135. Banerji U, O'Donnell A, Scurr M, et al. Phase I Pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005, 23:4152.
136. Tolcher AW, Hao D, de Bono J, et al. Phase I, Pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol 2006, 24:2052.